LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2

Biochemical and Biophysical Research Communications

Volumn 437, Issue 4, 2013, Pages 565-572

  Qi, Xu chen ^a   Xie, Da jiang ^a   Yan, Qing feng ^b   Wang, Yi rong ^a   Zhu, Yin xin ^a   Qian, Cong ^a   Yang, Shu xu ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Bcl 2; EGFR; Glioblastoma; LRIG1; Temozolomide; Topoisomerase 2

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN BCL 2; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; GLIOBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

, LEUCINE-RICH REPEATS AND IMMUNOGLOBULIN-LIKE DOMAINS 1; BCL-2; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; GBM; GLIOBLASTOMA; GLIOBLASTOMA MULTIFORME; LRIG1; MAMMALIAN TARGET OF RAPAMYCIN; MTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PI3K; RNAI RNA INTERFERENCE; TEMOZOLOMIDE; TMZ; TOPO-2; TOPOISOMERASE-2;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; DNA TOPOISOMERASES, TYPE II; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE;

MAMMALIA;

EID: 84881542417     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.116     Document Type: Article

References (31)

1. Lacroix M., Abi-Said D., Fourney D.R., Gokaslan Z.L., Shi W., DeMonte F., Lang F.F., McCutcheon I.E., Hassenbusch S.J., Holland E., Hess K., Michael C., Miller D., Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 2001, 95:190-198.
2. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
3. Weller M., Felsberg J., Hartmann C., Berger H., Steinbach J.P., Schramm J., Westphal M., Schackert G., Simon M., Tonn J.C., Heese O., Krex D., Nikkhah G., Pietsch T., Wiestler O., Reifenberger G., von Deimling A., Loeffler M. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin. Oncol. 2009, 27:5743-5750.
4. Dahlback H.S., Brandal P., Meling T.R., Gorunova L., Scheie D., Heim S. Genomic aberrations in 80 cases of primary glioblastoma multiforme: pathogenetic heterogeneity and putative cytogenetic pathways. Genes Chromosom. Cancer 2009, 48:908-924.
5. Smith J.S., Tachibana I., Passe S.M., Huntley B.K., Borell T.J., Iturria N., O'Fallon J.R., Schaefer P.L., Scheithauer B.W., James C.D., Buckner J.C., Jenkins R.B. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer Inst. 2001, 93:1246-1256.
6. Barker F.G., Simmons M.L., Chang S.M., Prados M.D., Larson D.A., Sneed P.K., Wara W.M., Berger M.S., Chen P., Israel M.A., Aldape K.D. EGFR overexpression and radiation response in glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51:410-418.
7. Cao C., Lu S., Sowa A., Kivlin R., Amaral A., Chu W., Yang H., Di W., Wan Y. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Lett. 2008, 266:249-262.
8. Cao C., Huang X., Han Y., Wan Y., Birnbaumer L., Feng G.-S., Marshall J., Jiang M., Chu W.-M. Galpha(i1) and Galpha(i3) are required for epidermal growth factor-mediated activation of the Akt-mTORC1 pathway. Sci. Signal 2009, 2:ra17.
9. Dikic I. Mechanisms controlling EGF receptor endocytosis and degradation. Biochem. Soc. Trans. 2003, 31:1178-1181.
10. Shilo B.Z. Signaling by the Drosophila epidermal growth factor receptor pathway during development. Exp. Cell Res. 2003, 284:140-149.
11. Laederich M.B., Funes-Duran M., Yen L., Ingalla E., Wu X., Carraway K.L., Sweeney C. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J. Biol. Chem. 2004, 279:47050-47056.
12. Ye F., Gao Q., Xu T., Zeng L., Ou Y., Mao F., Wang H., He Y., Wang B., Yang Z., Guo D., Lei T. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. J. Neurooncol. 2009, 94:183-194.
13. Thomasson M., Hedman H., Guo D., Ljungberg B., Henriksson R. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis. Br. J. Cancer 2003, 89:1285-1289.
14. Ljuslinder I., Golovleva I., Palmqvist R., Oberg A., Stenling R., Jonsson Y., Hedman H., Henriksson R., Malmer B. LRIG1 expression in colorectal cancer. Acta Oncol. 2007, 46:1118-1122.
15. Xie R., Yang H., Xiao Q., Mao F., Zhang S., Ye F., Wan F., Wang B., Lei T., Guo D. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation. Oncol. Rep. 2013, 29:177-184.
16. Goldoni S., Iozzo R.A., Kay P., Campbell S., McQuillan A., Agnew C., Zhu J.X., Keene D.R., Reed C.C., Iozzo R.V. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 2007, 26:368-381.
17. Chen M.B., Wu X.Y., Gu J.H., Guo Q.T., Shen W.X., Lu P.H. Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem. Biophys. 2011, 60:311-322.
18. Ledda F., Bieraugel O., Fard S.S., Vilar M., Paratcha G. Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J. Neurosci. 2008, 28:39-49.
19. Mao F., Wang B., Xi G., Sun W., Zhang H., Ye F., Guo D., Lei T. Effects of RNAi-mediated gene silencing of LRIG1 on proliferation and invasion of glioma cells. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2012, 32:227-232.
20. Lin Y.L., Yuksel Durmaz Y., Nor J.E., Elsayed M.E. Synergistic combination of small molecule inhibitor and rna interference against antiapoptotic Bcl-2 protein in head and neck cancer cells. Mol. Pharm. 2013, 10(7):2730-2738.
21. Weyland M., Griveau A., Bejaud J., Benoit J.P., Coursaget P., Garcion E. Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells. Int. J. Pharm. 2013.
22. 6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int. J. Cancer 1996, 65:506-512.
23. Kaina B., Fritz G., Mitra S., Coquerelle T. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 1991, 12:1857-1867.
24. Meikrantz W., Bergom M.A., Memisoglu A., Samson L. O6-alkylguanine DNA lesions trigger apoptosis. Carcinogenesis 1998, 19:369-372.
25. 6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat. Res. 1997, 381:227-241.
26. 6-methylguanine. Oncogene 2007, 26:186-197.
27. Taverna P., Liu L., Hwang H.S., Hanson A.J., Kinsella T.J., Gerson S.L. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat. Res. 2001, 485:269-281.
28. Nadkarni A., Shrivastav M., Mladek A.C., Schwingler P.M., Grogan P.T., Chen J., Sarkaria J.N. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. J. Neurooncol. 2012, 110:349-357.
29. Nitiss J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 2009, 9:338-350.
30. Shrivastav M., De Haro L.P., Nickoloff J.A. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008, 18:134-147.
31. Zhang W.B., Wang Z., Shu F., Jin Y.H., Liu H.Y., Wang Q.J., Yang Y. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J. Biol. Chem. 2010, 285:40461-40471.